Entera Bio (ENTX) News Today → A ‘DeFi Summer’ Projected! (From Crypto 101 Media) (Ad) Free ENTX Stock Alerts $2.62 +0.11 (+4.38%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 8:42 AM | marketbeat.comHC Wainwright Analysts Decrease Earnings Estimates for Entera Bio Ltd. (NASDAQ:ENTX)Entera Bio Ltd. (NASDAQ:ENTX - Free Report) - Equities researchers at HC Wainwright cut their Q4 2024 earnings estimates for Entera Bio in a research note issued to investors on Monday, May 13th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.07) per shaMay 15 at 8:00 AM | globenewswire.comEntera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board MemberMay 15 at 3:08 AM | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for Entera Bio (NASDAQ:ENTX)May 13 at 9:24 PM | markets.businessinsider.comPositive Outlook for Entera Bio with Buy Rating and Promising Pipeline DevelopmentsMay 13 at 8:20 AM | marketbeat.comEntera Bio's (ENTX) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Entera Bio in a report on Monday.May 13 at 7:00 AM | globenewswire.comEntera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024May 11, 2024 | marketbeat.comEntera Bio Ltd. (NASDAQ:ENTX) Short Interest UpdateEntera Bio Ltd. (NASDAQ:ENTX - Get Free Report) saw a large decrease in short interest in April. As of April 30th, there was short interest totalling 35,200 shares, a decrease of 60.8% from the April 15th total of 89,900 shares. Based on an average daily volume of 245,300 shares, the short-interest ratio is presently 0.1 days.May 10, 2024 | investorplace.comENTX Stock Earnings: Entera Bio Beats EPS for Q1 2024May 10, 2024 | globenewswire.comEntera Bio Reports Q1 2024 Financial Results and Provides Business UpdatesApril 30, 2024 | finance.yahoo.comAre Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?April 15, 2024 | investorplace.comCan You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?April 10, 2024 | marketbeat.comEntera Bio Ltd. (NASDAQ:ENTX) Short Interest Up 988.9% in MarchEntera Bio Ltd. (NASDAQ:ENTX - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 88,200 shares, an increase of 988.9% from the March 15th total of 8,100 shares. Based on an average daily trading volume, of 161,500 shares, the short-interest ratio is presently 0.5 days.April 8, 2024 | globenewswire.comEntera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral ResearchApril 4, 2024 | marketbeat.comQ1 2024 EPS Estimates for Entera Bio Ltd. (NASDAQ:ENTX) Lifted by HC WainwrightEntera Bio Ltd. (NASDAQ:ENTX - Free Report) - Research analysts at HC Wainwright raised their Q1 2024 earnings per share (EPS) estimates for shares of Entera Bio in a note issued to investors on Tuesday, April 2nd. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.March 26, 2024 | globenewswire.comEntera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 MonthsMarch 23, 2024 | finance.yahoo.comWe Think Entera Bio (NASDAQ:ENTX) Can Afford To Drive Business GrowthMarch 20, 2024 | globenewswire.comEntera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel SyndromeMarch 12, 2024 | finanznachrichten.deEntera Bio Ltd.: Entera Bio Announces Full Year 2023 Financial Results and Provides Business UpdatesMarch 9, 2024 | finance.yahoo.comENTX May 2024 5.000 callMarch 8, 2024 | globenewswire.comEntera Bio Announces Full Year 2023 Financial Results and Provides Business UpdatesMarch 6, 2024 | investing.comEntera Bio regains NASDAQ compliance with bid priceMarch 4, 2024 | finanznachrichten.deEntera Bio Ltd.: Entera Bio Regains Compliance with Nasdaq Minimum Bid Price RequirementMarch 4, 2024 | globenewswire.comEntera Bio Regains Compliance with Nasdaq Minimum Bid Price RequirementFebruary 17, 2024 | finance.yahoo.comENTX Mar 2024 2.500 callJanuary 30, 2024 | finance.yahoo.comEntera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 20, 2024 | ca.finance.yahoo.comENTX Jan 2024 10.000 callJanuary 3, 2024 | finance.yahoo.comEntera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price RuleDecember 31, 2023 | benzinga.comEntera Bio Stock (NASDAQ:ENTX), Short Interest ReportDecember 27, 2023 | benzinga.comEntera Bio Stock (NASDAQ:ENTX) Dividends: History, Yield and DatesDecember 26, 2023 | benzinga.comEntera Bio Stock (NASDAQ:ENTX), Analyst Ratings, Price Targets, PredictionsDecember 26, 2023 | finance.yahoo.comEntera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025November 29, 2023 | finance.yahoo.comInterim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide PlatformNovember 27, 2023 | msn.comEntera Bio (ENTX) Price Target Increased by 66.67% to 10.20November 14, 2023 | baystreet.caEntera Bio Flat on Release of Q3 NumbersNovember 14, 2023 | msn.comEntera Bio GAAP EPS of -$0.08November 14, 2023 | finance.yahoo.comEntera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in DevelopmentNovember 11, 2023 | morningstar.comEntera Bio Ltd ENTXNovember 9, 2023 | finance.yahoo.comEntera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for OsteoporosisOctober 16, 2023 | finance.yahoo.comEntera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual MeetingSeptember 13, 2023 | finance.yahoo.comOPKO Health (OPK) Ties Up for Oral Peptide Tablet FormulationsSeptember 5, 2023 | finance.yahoo.comEntera Bio to Participate in Upcoming Investor ConferencesAugust 16, 2023 | finance.yahoo.comEntera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual MeetingAugust 12, 2023 | finanznachrichten.deEntera Bio Ltd.: Entera Bio Announces Q2 2023 Financial Results and Corporate UpdatesAugust 11, 2023 | finance.yahoo.comEntera Bio Announces Q2 2023 Financial Results and Corporate UpdatesJune 7, 2023 | finanznachrichten.deEntera Bio Ltd.: Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of DirectorsJune 7, 2023 | technews.tmcnet.comEntera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of DirectorsMay 7, 2023 | finance.yahoo.comEntera Bio First Quarter 2023 Earnings: US$0.076 loss per share (vs US$0.13 loss in 1Q 2022)May 6, 2023 | finanznachrichten.deEntera Bio Ltd.: Entera Bio Announces Q1 2023 Financial Results and Corporate UpdatesMay 5, 2023 | finance.yahoo.comEntera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue EstimatesMay 5, 2023 | msn.comEntera Bio: Q1 Earnings Insights Get Entera Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Top 5 AI Stocks to Buy for 2024 (Ad)5 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist. Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In" ENTX Media Mentions By Week ENTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ENTX News Sentiment▼0.670.55▲Average Medical News Sentiment ENTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ENTX Articles This Week▼141▲ENTX Articles Average Week Get Entera Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Atara Biotherapeutics News Today CEL-SCI News Today Protara Therapeutics News Today Instil Bio News Today Turnstone Biologics News Today Cognition Therapeutics News Today Ikena Oncology News Today Precision BioSciences News Today Elutia News Today Gritstone bio News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ENTX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsTop 5 AI Stocks to Buy for 2024Market Moving TrendsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportPharma Giant Makes Deal with a "Drug Smuggler"Behind the MarketsTop 5 Tech Stocks to Buy for 2024Daily Market Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
